Table 1.

Baseline characteristics of patients in the study group as a whole (overall) and in patients with complete, partial, or no remission or who received rituximab as first- or second-line therapy, considered separately

CharacteristicOverall
(n=100)Complete Remission (n=27)Partial Remission (n=38)No Remission (n=35)First-Line Therapy (n=68)Second-Line Therapy (n=32)
Age (yr)51.5±5.948.9±16.551.4±15.653.7±15.955.0±16.444.1±12.0a
Male sex, n (%)72 (72)13 (48.1)b28 (73.7)31 (87.5)46 (67.6)26 (81.3)
Clinical parameters
 body weight (kg)76.2±13.670.5±15.678.2±12.278.3±12.776.1±12.176.5±16.5
 systolic BP (mmHg)130 (122–144)129 (119.5–139)132.5 (123–150)135.5 (127–145)130 (123–146)130 (121–140)
 diastolic BP (mmHg)82 (74–90)80 (73.5–86.5)84 (76–90)83 (75–90)84 (72.5–90)81 (76–86)
Laboratory parameters
 serum creatinine (mg/dl)1.2 (0.97–1.7)1.01 (0.84–1.13)b,c 1.2 (1–1.6)1.6 (1.1–2.4)1.2 (0.95–1.8)1.1 (0.97–1.6)
 serum albumin (g/dl)2.2±0.62.5±0.6b2.2±0.72.0±0.52.2±0.62.2±0.6
 total cholesterol (mg/dl)272 (214–318)232.5 (209–295)277 (206–318)288 (225–351)257 (214–320)288 (221–314.5)
 HDL cholesterol (mg/dl)52 (42–65)63 (51–73)b,c49 (42–61)48 (39–58)54 (42–66)47.5 (40–60.5)
 triglycerides (mg/dl)158 (110–228)110 (80–147)b,c146 (130–205)b227 (142–300)142 (100–223)191 (134.5–256.5)
 proteinuria (g/24 h)9.1 (5.8–12.8)5.8 (4.3–9.6)b8.2 (5.8–11.2)b12.9 (9.4–18.5)9.3 (5.8–12.7)9 (6.4–13.3)
 duration of persistent proteinuria (mo)25.5 (11.7–67.7)23.4 (12.3–63.6)20.6 (11.9–66.3)32.5 (11–76.4)16.7 (9.2–31.4)65.4 (35–80.5)a
  • Variables expressed as mean ± SD are compared using one-way ANOVA. Variables expressed as median (IQR) are compared using the Kruskal–Wallis test. Categorical variables are expressed in percentages and compared using the chi-squared test.

  • a P<0.05 versus first-line therapy.

  • b P<0.05 versus no remission.

  • c P<0.05 versus partial remission.